The landscape of obesity management is undergoing a significant transformation, moving beyond the singular reliance on GLP-1 receptor agonists like semaglutide and tirzepatide. A 2026 update to the Practice Guide on Obesity and Weight Management, Education, and Resources (POWER) framework emphasizes that while these medications are revolutionary, they represent only one component of a comprehensive, multidisciplinary approach to treating obesity as a chronic, systemic disease. The authors advocate for a shift away from traditional body mass index (BMI) metrics toward more holistic health assessments. By integrating pharmacological interventions with endoscopic bariatric therapies and surgical procedures, clinicians can achieve more sustainable and significant weight loss outcomes. This evolution reflects a broader commitment to personalized medicine, where genetic insights and individual patient profiles guide the selection of therapeutic combinations. Gastroenterologists and hepatologists are positioned at the forefront of this shift, managing the complex interplay between obesity and related conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD) and gastroesophageal reflux disease (GERD). The updated framework provides a structured, multidisciplinary process designed to optimize patient care through evidence-based, multi-modal strategies. For patients and practitioners, the future of obesity care lies in the strategic combination of therapies rather than reliance on a single drug class. This approach promises to improve long-term health outcomes by addressing the systemic nature of obesity through tailored, multi-disciplinary interventions that evolve alongside emerging medical research and technological advancements.
